In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) - PubMed (original) (raw)
Comparative Study
. 2005 Jul 5;46(1):57-64.
doi: 10.1016/j.jacc.2005.03.051.
Affiliations
- PMID: 15992636
- DOI: 10.1016/j.jacc.2005.03.051
Free article
Comparative Study
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
William T Abraham et al. J Am Coll Cardiol. 2005.
Free article
Abstract
Objectives: We sought to compare the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving parenteral treatment with one of four intravenous vasoactive medications.
Background: There are limited data regarding the effects of the choice of intravenous vasoactive medication on in-hospital mortality in patients hospitalized with ADHF.
Methods: This was a retrospective analysis of observational patient data from the Acute Decompensated Heart Failure National Registry (ADHERE), a multicenter registry designed to prospectively collect data on each episode of hospitalization for ADHF and its clinical outcomes. Data from the first 65,180 patient episodes (October 2001 to July 2003) were included in this analysis. Cases in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were identified and reviewed (n = 15,230). Risk factor and propensity score-adjusted odds ratios (ORs) for in-hospital mortality were calculated.
Results: Patients who received intravenous nitroglycerin or nesiritide had lower in-hospital mortality than those treated with dobutamine or milrinone. The risk factor and propensity score-adjusted ORs for nitroglycerin were 0.69 (95% confidence interval [CI] 0.53 to 0.89, p < or = 0.005) and 0.46 (94% CI 0.37 to 0.57, p < or = 0.005) compared with milrinone and dobutamine, respectively. The corresponding values for nesiritide compared with milrinone and dobutamine were 0.59 (95% CI 0.48 to 0.73, p < or = 0.005) and 0.47 (95% CI 0.39 to 0.56, p < or = 0.005), respectively. The adjusted OR for nesiritide compared with nitroglycerin was 0.94 (95% CI 0.77 to 1.16, p = 0.58).
Conclusions: Therapy with either a natriuretic peptide or vasodilator was associated with significantly lower in-hospital mortality than positive inotropic therapy in patients hospitalized with ADHF. The risk of in-hospital mortality was similar for nesiritide and nitroglycerin.
Comment in
- Acute decompensated heart failure: the shrinking role of inotropic therapy.
Dec GW. Dec GW. J Am Coll Cardiol. 2005 Jul 5;46(1):65-7. doi: 10.1016/j.jacc.2005.04.007. J Am Coll Cardiol. 2005. PMID: 15992637 No abstract available.
Similar articles
- Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Arnold LM, et al. Pharmacotherapy. 2006 Aug;26(8):1078-85. doi: 10.1592/phco.26.8.1078. Pharmacotherapy. 2006. PMID: 16863484 - Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM. Maisel AS, et al. J Am Coll Cardiol. 2008 Aug 12;52(7):534-40. doi: 10.1016/j.jacc.2008.05.010. J Am Coll Cardiol. 2008. PMID: 18687247 - Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
Saltzberg MT. Saltzberg MT. Rev Cardiovasc Med. 2004;5 Suppl 4:S17-27. Rev Cardiovasc Med. 2004. PMID: 15627915 Review. - Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC, Zhu DM, Shan YX. Wang XC, et al. Am J Cardiovasc Drugs. 2015 Dec;15(6):429-37. doi: 10.1007/s40256-015-0134-3. Am J Cardiovasc Drugs. 2015. PMID: 26123415 Review.
Cited by
- Elevated Plasma Big Endothelin-1 at Admission Is Associated With Poor Short-Term Outcomes in Patients With Acute Decompensated Heart Failure.
Mo R, Yang YM, Yu LT, Tan HQ, Zhu J. Mo R, et al. Front Cardiovasc Med. 2021 Mar 11;8:629268. doi: 10.3389/fcvm.2021.629268. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33778022 Free PMC article. - The evolving landscape of quality measurement for heart failure.
Fitzgerald AA, Allen LA, Masoudi FA. Fitzgerald AA, et al. Ann N Y Acad Sci. 2012 Apr;1254:131-139. doi: 10.1111/j.1749-6632.2012.06483.x. Ann N Y Acad Sci. 2012. PMID: 22548579 Free PMC article. Review. - Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model.
George I, Xydas S, Klotz S, Hay I, Ng C, Chang J, Xu K, Li Z, Protter AA, Wu EX, Oz MC, Wang J. George I, et al. J Cardiovasc Pharmacol. 2010 Jan;55(1):14-20. doi: 10.1097/FJC.0b013e3181c5e743. J Cardiovasc Pharmacol. 2010. PMID: 19858735 Free PMC article. - Efficacy of Milrinone and Dobutamine in Cardiogenic Shock: An Updated Systematic Review and Meta-Analysis.
Abdel-Razek O, Di Santo P, Jung RG, Parlow S, Motazedian P, Prosperi-Porta G, Visintini S, Marbach JA, Ramirez FD, Simard T, Labinaz M, Mathew R, Hibbert B. Abdel-Razek O, et al. Crit Care Explor. 2023 Aug 28;5(9):e0962. doi: 10.1097/CCE.0000000000000962. eCollection 2023 Sep. Crit Care Explor. 2023. PMID: 37649849 Free PMC article. Review. - Therapy for acute heart failure syndromes.
Donlan SM, Quattromani E, Pang PS, Gheorghiade M. Donlan SM, et al. Curr Cardiol Rep. 2009 May;11(3):192-201. doi: 10.1007/s11886-009-0028-6. Curr Cardiol Rep. 2009. PMID: 19379639 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical